An­oth­er Eylea threat: Roche ex­pands la­bel for block­buster eye drug Vabysmo

With hopes of de­thron­ing Re­gen­eron’s block­buster eye drug fran­chise Eylea, Roche on Thurs­day an­nounced the FDA has ex­pand­ed the la­bel of its own block­buster eye drug Vabysmo (faricimab-svoa) to a third in­di­ca­tion, this time for the treat­ment of mac­u­lar ede­ma fol­low­ing reti­nal vein oc­clu­sion (RVO).

The new in­di­ca­tion for the bis­pe­cif­ic an­ti­body is based on two Phase III stud­ies that Roche said demon­strat­ed ear­ly and sus­tained vi­sion im­prove­ments that were non-in­fe­ri­or to Eylea. RVO is the sec­ond-most com­mon cause of vi­sion loss due to reti­nal vas­cu­lar con­di­tions, and Roche said it af­fects more than one mil­lion peo­ple in the US, main­ly se­niors, and can lead to se­vere and sud­den vi­sion loss.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER